Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01
Published July 6, 2022 · Recall initiated: May 23, 2022
Summary
FDA records drug Class I recall D-1166-2022, published July 6, 2022 and initiated May 23, 2022. Recalling firm: Akcea Therapeutics, Inc.; Status: Terminated; Reported quantity: 450 cartons; Lot: Lots: 028C21AB, 028C21AC, Exp. 05/2025. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Akcea Therapeutics, Inc.
- Distributor
- KY, USA
- Lot
- Lots: 028C21AB, 028C21AC, Exp. 05/2025
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDASnoreStop NasoSpray, 0.3 FL OZ (9 mL), Green Pharmaceuticals Inc. Camarillo, CA 93012, NDC 61152-199-99, UPC 7July 6, 2022
- FDADaytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Contains: 30 Patches, RxJuly 6, 2022
- FDALosartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg, 30, 90 & 1000 count NDC # 33342-052-07, NDCJuly 6, 2022
- FDACalcipotriene Topical Solution, 0.005% (Scalp Solution), Rx only, 60 mL (2 fl. oz.) bottle, Manufactured by:July 6, 2022
- FDALosartan Potassium Tablets, USP 100 mg, 90 Tablets bottles, Rx Only, Marketed and Packaged By: PD-RxJuly 6, 2022
- FDADesmopressin Acetate Tablets, 0.2 mg, 100-count bottles, Rx Only, Manufactured for: Northstar Rx LLC, Memphis,July 6, 2022
Questions about this recall
Was Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01 recalled?
Yes. FDA published recall D-1166-2022 on July 6, 2022. Reported hazard: Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail